New York State Common Retirement Fund Increases Position in 10x Genomics, Inc. (NASDAQ:TXG)

New York State Common Retirement Fund lifted its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 0.6% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 642,915 shares of the company’s stock after buying an additional 3,994 shares during the period. New York State Common Retirement Fund owned approximately 0.54% of 10x Genomics worth $35,978,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of TXG. UMB Bank n.a. lifted its position in shares of 10x Genomics by 51.6% during the fourth quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after acquiring an additional 266 shares in the last quarter. AIA Group Ltd lifted its position in shares of 10x Genomics by 0.9% during the fourth quarter. AIA Group Ltd now owns 41,369 shares of the company’s stock worth $2,315,000 after acquiring an additional 365 shares in the last quarter. Xponance Inc. lifted its position in shares of 10x Genomics by 3.2% during the third quarter. Xponance Inc. now owns 13,060 shares of the company’s stock worth $539,000 after acquiring an additional 400 shares in the last quarter. Parametrica Management Ltd lifted its position in shares of 10x Genomics by 3.4% during the third quarter. Parametrica Management Ltd now owns 15,300 shares of the company’s stock worth $631,000 after acquiring an additional 500 shares in the last quarter. Finally, Mirador Capital Partners LP lifted its position in shares of 10x Genomics by 1.9% during the fourth quarter. Mirador Capital Partners LP now owns 27,885 shares of the company’s stock worth $1,560,000 after acquiring an additional 521 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TXG. Stifel Nicolaus dropped their target price on 10x Genomics from $68.00 to $63.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Finally, Barclays decreased their price target on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, 10x Genomics presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.22.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 1,000 shares of 10x Genomics stock in a transaction on Friday, February 9th. The shares were sold at an average price of $49.53, for a total transaction of $49,530.00. Following the transaction, the chief executive officer now owns 855,381 shares in the company, valued at approximately $42,367,020.93. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other 10x Genomics news, insider Benjamin J. Hindson sold 2,613 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total value of $121,086.42. Following the sale, the insider now owns 283,059 shares in the company, valued at approximately $13,116,954.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Serge Saxonov sold 1,000 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $49.53, for a total transaction of $49,530.00. Following the completion of the sale, the chief executive officer now owns 855,381 shares in the company, valued at approximately $42,367,020.93. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,959 shares of company stock worth $592,806. 10.65% of the stock is owned by corporate insiders.

10x Genomics Trading Down 2.3 %

Shares of 10x Genomics stock opened at $26.90 on Friday. The company’s fifty day simple moving average is $38.12 and its 200-day simple moving average is $42.60. 10x Genomics, Inc. has a 1-year low of $26.30 and a 1-year high of $63.57.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The firm had revenue of $183.98 million for the quarter, compared to analysts’ expectations of $182.73 million. During the same quarter last year, the firm posted ($0.15) EPS. The firm’s quarterly revenue was up 17.8% compared to the same quarter last year. As a group, research analysts predict that 10x Genomics, Inc. will post -1.47 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.